key: cord-0758188-dodst8fm authors: Tejada Meza, Herbert; Lambea Gil, Álvaro; Sancho Saldaña, Agustín; Martínez‐Zabaleta, Maite; Garmendia Lopetegui, Eñaut; López‐Cancio, Elena; Castañón Apilánez, María; Herrera Isasi, María; Marta Enguita, Juan; Gómez‐Vicente, Beatriz; Arenillas, Juan F.; Arenaza Basterrechea, Naroa; Timiraos Fernández, Juan José; Sánchez Herrero, Joaquín; Maciñeiras Montero, José Luis; Castellanos Rodrigo, Mar; Fernández‐Coud, Dolores; Casado Menéndez, Ignacio; Temprano Fernández, María Teresa; Freijo, María del Mar; Luna, Alain; Palacio Portilla, Enrique Jesús; Jiménez López, Yésica; Rodríguez‐Castro, Emilio; Rodríguez‐Yáñez, Manuel; Tejada García, Javier; Beltrán Rodríguez, Iria; Julián‐Villaverde, Francisco; Moreno García, Maria Pilar; Trejo Gabriel‐Galán, José María; Echavarría Iñiguez, Ana; Pérez Lázaro, Cristina; Navarro Pérez, Maria Pilar; Marta Moreno, Javier title: Impact of COVID‐19 outbreak in reperfusion therapies of acute ischemic stroke in North‐West Spain date: 2020-08-06 journal: Eur J Neurol DOI: 10.1111/ene.14467 sha: 8e6df5399199cfca9d9a935fa5bf6dd94ff021ad doc_id: 758188 cord_uid: dodst8fm Since the first reported case in early December 2019, severe acute respiratory coronavirus 2 (SARS‐CoV‐2) infection, known as Coronavirus Disease 2019 (COVID‐19), has spread all over the world (1‐3). As of June 4th, more than 6 million cases and 350,000 deaths have been reported worldwide (4). Treating these patients and containing the outbreak has become the main priority in any center, arising the risk of possible collateral damage on patients with other acute diseases due to the collapse of the pre‐ and intra‐hospital emergency care systems. Since the first reported case in early December 2019, severe acute respiratory coronavirus 2 (SARS-CoV-2) infection, known as Coronavirus Disease 2019 (COVID-19), has spread all over the world (1) (2) (3) . As of June 4th, more than 6 million cases and 350,000 deaths have been reported worldwide (4) . Treating these patients and containing the outbreak has become the main priority in any center, arising the risk of possible collateral damage on patients with other acute diseases due to the collapse of the pre-and intra-hospital emergency care systems. Spain has been one of the countries more heavily stricken by SARS-CoV-2, with some regions archiving more than 3,000 cases per day. In this context, a decrease in the number of hospital admissions for ischemic strokes has also been described in different regions of the country, in addition to a local report of disruption in their extra and intra-hospital pathways (5) (6) (7) (8) . The aim of this study is to analyze the impact of the COVID-19 epidemic outbreak on the reperfusion therapies, i.e., intravenous thrombolysis (IVT) and endovascular treatment (EVT), for acute ischemic stroke in the North-West of Spain. We examine its impact on hospital admissions, extra and intra-hospital times of action and short-term outcome. This Spanish multicenter retrospective observational study was based on the NORDICTUS web-based prospective reperfusion registry. NORDICTUS is a research and innovation network in cerebrovascular diseases that brings together all public hospitals with stroke units in North-West Spain, with a global catchment area of 11.5 million inhabitants. According to its territorial division, Spain is divided into seventeen autonomous communities (AC) and two autonomous cities. Both groups are a first-order political and administrative division in the country, and NORDICTUS covers eight of them. Sixteen of the eighteen referral centers of the network offered their data, including twelve of the thirteen centers that perform endovascular treatment in the region. During the pandemic, none of the participating regions has changed its pre-hospital ischemic stroke care. Epidemiological data of COVID-19 cases were obtained from the Ministry of Health, Consumer Affairs and Social Welfare. Patients with a PCR positive for SARS-CoV-2 were considered confirmed cases. Due to a change in the counting system in the AC of Galicia, historical data from that administration were obtained from its regional Department of Health (Conselleria de Sanidade) (9,10). We included all consecutive patients with an ischemic stroke that received IVT or EVT in tertiary hospitals of the NORDICTUS network between December 30th, 2019 and May 3rd, 2020. Cases were grouped into two periods, according to the setting of the state of emergency in Spain (March 14th, 2020). We considered the start of the COVID-19 period the 11th week This article is protected by copyright. All rights reserved COVID-19 diagnostic test results. We selected, as short-term outcome variables, hemorrhagic transformation after reperfusion therapies and in-hospital mortality. COVID-19 diagnosis was done using polymerase chain reaction (PCR) techniques of nasopharyngeal swabs for SARS-CoV-2. We used descriptive statistics to compare the incidence of stroke admissions before and after the setting of the state of emergency in Spain, expressed in strokes per week (W), and the differences between the other study variables in those periods. Qualitative variables are described using counts and percentages, and continuous quantitative variables as means with standard deviation and medians with interquartile ranges, when necessary. Comparisons between groups were made using chi-square tests for comparing categorical variables and the Student Test or Mann-Whitney U test for continuous variables. Multiple logistic regression was used to identify factors associated with short-term outcome variables in those subgroups in which a significant difference was found. P values <0.05 were considered statistically significant. Statistical analysis was performed with SPSS Statistics 20. The study was approved by the local Ethics Committee of each participating center. The treatment of every data obtained in the registry was done following the Spanish data protection law (Data Protection and Digital Rights Guarantee Act). In total, 796 patients with acute ischemic stroke (male 409, 51.4%; average age 74.2 years SD ± 13.0), received reperfusion therapies in the study period: 362 (45.5%) EVT alone, 159 (20.0%) bridging rtPA before EVT, and 275 (34.5%) only IVT. Table 1 shows the comparison of baseline characteristics of the patients before and after the setting of the state of emergency. There was an increase in the number of patients brought to the hospital by ambulance (46.5% vs. 55.2%, p = 0.019), a worsening in ASPECTS punctuations on arrival This article is protected by copyright. All rights reserved (10 vs. 9, p = 0.003), and an increase in strokes of undetermined origin (31.2% vs. 39.6%, p = 0.020) after the setting of the state of emergency. week decreased once the state of emergency was declared, compared to the number of patients treated before (46.5 patients per week vs. 39.0 patients per week, p = 0,043). For EVT, we found a decrease in those who received general anesthesia (57.0% vs. 42.4%, p = 0.002) and in the proportion of successful recanalization (92.9% vs. 86.6%, p = 0.016) ( Table 2 ). In terms of treatment times, there was an increase in DDT (95.0 vs. 110.0 minutes, p = 0.001) and DNT (51.0 vs. 55.0, p = 0.038), with no significant difference in the other recorded times (Table 3) . Regarding in-hospital mortality, no differences were found considering the whole cohort of patients. In the subgroups analysis, only the group of COVID-19 positive patients, compared with the COVID-19 negative ones (37.5% vs. 9.9%, p = 0.002) (Table S1 in the Data Supplement) and the group of patients that received IVT alone had higher in-hospital mortality (3.9% vs. 13.4%, p = 0.004) ( Table 4) . After a multivariate analysis using logistic regression in this latter (adjusted for age and those variables that were significantly different between both periods), being COVID-19 positive was significantly associated with higher inhospital mortality (Table S2 in the Data Supplement and Table 5 ). There has been a decrease in hospital admissions for ischemic stroke during the COVID-19 pandemic in some regions (5) (6) (7) (8) 11) . Among the possible causes, it has been suggested changes in social behavior, minor non-disabling strokes staying at home, or admission to hospital isolation units where stroke might not be the major issue and might be underrecognized. There is also a risk that not enough attention has been paid to diagnose it. (6) . Some of these factors may have also influenced the number of IVT or EVT in stroke patients, a worrying situation knowing the demonstrated benefit of these treatments on functional prognosis (12) (13) (14) . Data published so far, have not shown a decrease in the proportion of reperfusion treatments in admitted ischemic strokes (6, 8, 11) , but this data could be misleading. Considering that there is no reason to think of a real decrease in ischemic stroke incidence, but only in their hospital admissions, maintaining the same proportion of This article is protected by copyright. All rights reserved admissions treated with reperfusion therapies means a reduction in the proportion of patients treated from the totality of ischemic strokes. In our study, we found a significant decrease in the number of patients with ischemic stroke who received reperfusion therapy per week in the COVID-19 period without changes in the type of treatment received ( Figure 1 , Table 2 ). As seen in Figure 1 , in the last two weeks (W17 and W18), there was a rise in the number of reperfusion treatments performed, which seems to correlate with the increment in hospital admissions for ischemic stroke observed at this date in the study hospitals (6) . This situation could reflect the beginning of a "recovery" period, maybe as a consequence of the different campaigns carried out by the medical staff of most of the centers to raise awareness among the population of the importance of attending to the hospital when detecting stroke symptoms, despite limited free mobility and the risk of catching COVID-19 infection. We also found an increase in the proportion of patients that arrived at the hospital by ambulance. This could make sense considering the isolation measures taken by the government to contain the virus dissemination. However, it also means another problem, which is how to deal with the limited availability of ambulance fleets. This saturation of ambulances could explain the delay in the DDT of our patients, a fact specially observed in those transferred from other hospitals. The increment in DNT may be related to overwhelmed emergency departments and the new circuits established to manage strokes with suspected COVID-19 during this period. Some examples are the performance of relevant screening questions (respiratory symptoms, potential contact with a confirmed case, travel history), the concern about respiratory status and its management, the PCR testing when a COVID-19 case is suspected, the use of personal protection equipment, the disposal of potentially contaminated materials, or the sterilization of the contaminated CT control room. This is a new situation for stroke teams that often leads to great uncertainty and anxiety among healthcare workers who are in direct contact with patients, and this could have also contributed to the DNT delay. Given this explanation, the non-worsening in the DPT of our sample could be because globally, only a minority of patients who went to EVT received rtPA bridging therapy, so that the delay in DNT did not influence our DPT. Additionally, most of our neurointerventionalists canceled all scheduled activities and were fully available for This article is protected by copyright. All rights reserved emergencies focused on acute stroke treatment, which could have contributed to maintaining these times. We believe that pre-notification continues to be a cornerstone for maintaining good inhospital times of care. This will allow patients with high suspicions of SARS-CoV-2 infection to be expected with all the protection measures in place. Reinforcing public awareness of stroke warning signs and the importance of getting early to the hospital, even in this pandemic period, could also help improve extra-hospital attention times. As other authors have described, we did not find higher NIHSS in patients treated during the COVID-19 period (8), but we did find worse ASPECTS. This could be related to the longer out-of-hospital times previously described. Moreover, some patients might get out of the treatment group due to baseline characteristics associated with the increment of pre-hospital attention times. The decrease observed in the use of general anesthesia in EVT could obey the application of recommendations in our hospitals to minimize risky procedures such as intubation and avoid aerosols generation. We also found a decrease in the proportion of successful reperfusion (mTICI 2b -3) obtained after EVT. Currently, no study supports the fact that COVID-19 may be responsible for acute ischemic stroke with large vessel occlusions or clot composition. So this finding could be related to factors indirectly associated with the COVID-19 period, such as more organized thrombi due to the delay in out-of-hospital times detected in this period. The relationship between viral infections and ischemic stroke is well established, with an increased odds of stroke by 1.4-fold in these patients (16) . Ischemic strokes occur in about 2% of patients with COVID-19 infection during hospitalization (17) . A potential link between COVID-19 and stroke could make sense from a pathophysiological point of view. converting enzyme 2 (ACE2) receptor, potentially causing stroke by different mechanisms. Pro-inflammatory and prothrombotic states associated with COVID-19 infection could also predispose to thrombogenesis and therefore increase stroke risk. However, evidence of a causal relationship between COVID-19 and stroke is still limited, including those due to large vessel occlusion. In our sample, the proportion of COVID-19 patients in those who received reperfusion treatment was low. They had higher in-hospital mortality than negative COVID- This article is protected by copyright. All rights reserved 19 patients (tested by PCR) ( Table 1S in the Data Supplement), in accordance with other reports for different diseases and hospital processes that coexist with this infection (18) . In this study, we did not find a significant increase in in-hospital mortality in our patients' sample. Nevertheless, this happened in the group of patients that only received IVT, and this higher mortality was independently associated with a higher proportion of COVID-19 positive patients in this subgroup. There was an increase in overall mortality in ischemic strokes attended in our hospitals during the COVID-19 period, including those who were not candidates for reperfusion therapies (6) . The reasons for this global increase in in-hospital mortality still need to be elucidated, but among other causes, it is worth commenting that the hospital overload that occurred in this period could have resulted in a worse medical treatment by not admitting all of these patients to Stroke Units. Moreover, as previously described, stroke patients with COVID-19 infection may be at an increased risk of in-hospital mortality due to severe pneumonia, acute respiratory distress syndrome, and multi-organ failure, being cardiovascular and cerebrovascular disease markers of poor outcome in Finally, it is worth commenting on the increase in strokes of undetermined etiology in our sample, a situation that could be due to two causes. The first one would be related to the hospitals' collapse by COVID-19 patients, which even led to the use of Neurology inpatient beds for admission of these patients. In the pandemic scenery, the etiological study of stroke might have been limited to only those strictly necessary tests, without completing the standard study for these patients at discharge, which could have been premature due to the need for beds. The second one, more daring to hypothesize, could be due to the fact that "the eyes do not see what the mind does not know", and maybe, in this COVID-19 period, there have been new or less frequent causes of stroke that we have not taken into account. It may be possible that COVID-19 infection is related toischemic stroke etiologies that do not fit well into the classical ones. Although it did not reach statistical significance in our sample, 53.3% of COVID-19 positive strokes were labeled as of undetermined etiology vs. 34.1% of those that were COVID-19 negative (Table S1 in the Data Supplement). The role of hypercoagulability (20), vasculopathy, or even oxygen desaturation and eventual hypoperfusion in the most critically ill patients remains to be elucidated. This article is protected by copyright. All rights reserved Our study has some limitations. The main one is inherent to its retrospective, observational nature. Second, every center had its own COVID-19 testing protocol, and we did not investigate the incidence of COVID-19 infection among all patients with stroke without respiratory symptoms, which could have helped us understand the highest proportion of strokes of undetermined etiology during the COVID-19 period. Besides, we did not obtain other patient's characteristics that could correlate with the worse prognosis of COVID-19 patients, such as the severity of respiratory symptoms or the histopathological thrombus composition in these patients. Finally, the results might not be generalizable to other countries or regions with different stroke care protocols, geographic specificities, and different social and healthcare responses to the COVID-19 pandemic. This study offers a perspective about the impact of the COVID-19 pandemic in reperfusion therapies for acute ischemic stroke in a vast region, with a global catchment area of 11.5 million inhabitants, in one of the countries more heavily stricken by the SARS-CoV-2 epidemic. It shows a decrease in the number of patients treated, with a delay in out-ofhospital and door-to-needle times. For EVT, there was a decline in patients who received general anesthesia and in successful reperfusion rates. We did not find differences in the proportion of in-hospital mortality, except the subgroup of patients that only received IVT and those with COVID-19 confirmed infection. Among the measures to be taken in the event of a possible second COVID-19 outbreak, it is necessary to take into account both pre-and intra-hospital scenarios in order to maintain optimal care for patients with acute ischemic stroke. Furthermore, in our opinion, it would be interesting to establish an operational definition and a standard protocol for the study of cases in which a COVID-19 infection and a stroke coexist. The authors received no financial support for the research, authorship, and/or publication of this article. This article is protected by copyright. All rights reserved The data that support the findings of this study are available from the corresponding author upon reasonable request This article is protected by copyright. All rights reserved * On EVT patients. ^ Considering successful reperfusion as mTICI 2b-3 This article is protected by copyright. All rights reserved WHO declares COVID-19 a pandemic Covid-19 -Navigating the uncharted Covid-19: doctors are told not to perform CPR on patients in cardiac arrest Situación COVID-19 en España Ischaemic Stroke in the Time of Coronavirus Disease EXPRESS: Impact of COVID-19 outbreak in ischemic stroke admissions and in-hospital mortality in North-West Spain Acute Stroke Care Is at Risk in the Era of COVID-19. Experience at a Comprehensive Stroke Center in Barcelona Break in the Stroke Chain of Survival Due to COVID-19 Datos agregados notificados por las CCAA al Ministerio de Sanidad Xunta de Galiza. Datos de notificación de casos en Galicia Impact of the COVID-19 Epidemic on Stroke Care and Potential Solutions The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of Accepted Article This article is protected by copyright. All rights reserved individual patient data from five randomised trials Delayed presentation of acute ischemic strokes during the COVID-19 crisis Influenza-like illness as a trigger for ischemic stroke Neurological manifestations of hospitalized patients with covid-19 in wuhan, china: a retrospective case series study Mortality and Pulmonary Complications in Patients Age in years, mean (±SD) Atrial fibrillation, n (%) Small-vessel occlusion, n (%)